ArticleGastroenterology report2023

Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized-controlled open-label Phase II study.

Hangyu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.